GlycoMimetics Inc. has completed a reverse stock split at a ratio of 1-for-100 shares as part of its merger with Crescent Biopharma. Following the merger, each outstanding share of Crescent common stock was converted into 0.1445 shares of the new combined company. The new CUSIP number for the company is 38000Q201, and approximately 19.5 million shares of the combined company's common stock and equivalents are now outstanding. The company's shares are set to begin trading on the Nasdaq under the ticker symbol "CBIO."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.